RxDoctor Payments Data

Salman Razi, MD

Urology · Tracy, CANPI 1851368054

Payments from drug & device makers

$4,975in general payments, 2019–2025

Across 90 payments — averaging $55.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$3K
  • Intuitive Surgical$927
  • Medtronic$405
  • Accord Healthcare, Inc.$279
  • Teleflex LLC$243
  • Astellas Pharma US Inc$220
  • plus $266 from 7 others

What the payments were for

  • Travel & lodging$2,98960%
  • Food & beverage$1,93139%
  • Education$551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neotract Inc.18$2,637
Intuitive Surgical6$927
Medtronic(2 entities)10$405
Accord Healthcare, Inc.19$279
Teleflex LLC9$243
Astellas Pharma US Inc13$220
AbbVie(2 entities)5$85
Sumitomo Pharma America, Inc.3$60
Agiliti Surgical, Inc.2$43
Boston Scientific2$30
KARL Storz Endoscopy-america1$23
Ferring Pharmaceuticals Inc.1$12
Healthtronics Stone Solutions, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,975 in reported general payments places this provider in the 60th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$475,468
Medicare patients
557
Services billed
5,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron158$144,103
GemtesaVibegron14$16,053
Finasteride647$11,057
Tolterodine Tartrate95$9,042
Tamsulosin Hcl516$7,659
Trospium Chloride ErTrospium Chloride24$5,941
Oxybutynin Chloride112$1,784
Bicalutamide49$1,174
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim508$946
Doxazosin Mesylate44$631
Ciprofloxacin Hcl237$565
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$382
Dutasteride15$357
Cephalexin25$320
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$220$144,103158 claims
Sumitomo Pharma America, Inc.Gemtesa$60$16,05314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,324 urology providers in California.

Other urology in Tracy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →